Neurobo Pharmaceuticals Valuation
| NRBODelisted Stock | USD 1.89 0.11 5.50% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Neurobo Pharmaceuticals secures a last-minute Real Value of $1.73 per share. The latest price of the firm is $1.89. Our model forecasts the value of Neurobo Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of (1.18 M), shares owned by insiders of 65.23 %, and Return On Equity of -1.61 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Neurobo Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Neurobo Pharmaceuticals is based on 3 months time horizon. Increasing Neurobo Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neurobo Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neurobo Stock. However, Neurobo Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.89 | Real 1.73 | Hype 1.87 | Naive 1.79 |
The intrinsic value of Neurobo Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neurobo Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neurobo Pharmaceuticals helps investors to forecast how Neurobo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurobo Pharmaceuticals more accurately as focusing exclusively on Neurobo Pharmaceuticals' fundamentals will not take into account other important factors: Neurobo Pharmaceuticals Total Value Analysis
Neurobo Pharmaceuticals is now forecasted to have valuation of (1.18 M) with market capitalization of 20.33 M, debt of 203 K, and cash on hands of 8.85 M. The negative valuation of Neurobo Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Neurobo Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.18 M) | 20.33 M | 203 K | 8.85 M |
Neurobo Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neurobo Pharmaceuticals has an asset utilization ratio of 0.0307 percent. This suggests that the Company is making $3.07E-4 for each dollar of assets. An increasing asset utilization means that Neurobo Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Neurobo Pharmaceuticals Ownership Allocation
The market capitalization of Neurobo Pharmaceuticals is $20.33 Million. Neurobo Pharmaceuticals secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.23 % of Neurobo Pharmaceuticals outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Neurobo Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0.About Neurobo Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Neurobo Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Neurobo Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Neurobo Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Neurobo Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neurobo Pharmaceuticals. We calculate exposure to Neurobo Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neurobo Pharmaceuticals's related companies.NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Neurobo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Neurobo Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 5.1 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |